Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $135.08 Consensus Target Price from Brokerages

Abivax SA Sponsored ADR (NASDAQ:ABVX) has been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $135.0833.

A number of analysts recently commented on the company. Barclays began coverage on Abivax in a research report on Monday, October 13th. They set an “overweight” rating and a $142.00 price objective for the company. Citizens Jmp upped their price target on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research report on Tuesday, December 16th. Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a research note on Thursday, November 6th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, JMP Securities upped their target price on shares of Abivax from $95.00 to $114.00 and gave the company a “market outperform” rating in a report on Thursday, September 25th.

Hedge Funds Weigh In On Abivax

Several institutional investors and hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its holdings in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares during the period. First Horizon Corp purchased a new position in shares of Abivax during the 3rd quarter valued at about $36,000. Union Bancaire Privee UBP SA bought a new position in shares of Abivax during the 4th quarter valued at approximately $67,000. Hantz Financial Services Inc. bought a new position in shares of Abivax during the 3rd quarter valued at approximately $52,000. Finally, Gordian Capital Singapore Pte Ltd purchased a new stake in Abivax in the 3rd quarter worth approximately $76,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Abivax Trading Up 0.3%

Shares of ABVX stock opened at $117.10 on Wednesday. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax has a 12-month low of $4.77 and a 12-month high of $148.83. The stock has a market capitalization of $9.13 billion, a P/E ratio of -28.01 and a beta of 0.68. The firm’s 50 day moving average is $121.98 and its 200 day moving average is $88.44.

Abivax (NASDAQ:ABVX) last announced its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million for the quarter. Research analysts expect that Abivax will post -2.83 earnings per share for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.